Background
There is an unmet need for rapid assays predictive of efficacy for specific chemotherapy agents. In particular, for those patients with metastatic disease that have progressed on prior therapies. Newer multi-omic analysis can be performed on a single biopsy specimen and with rapid turn-around-time allowing greater clinical utility.